Instil Bio (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer, today reported its second quarter 2022…
Day: August 12, 2022
HCW Biologics (NASDAQ: HCWB) Reports Second Quarter 2022 Financial Results And Recent Business Highlights
HCW Biologics (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between chronic, low-grade inflammation and age-related diseases, today reported…